See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/236186890

# Identification of P-Glycoprotein Inhibitors in Contaminated Freshwater Sediments

ARTICLE in ENVIRONMENTAL SCIENCE & TECHNOLOGY · APRIL 2013

Impact Factor: 5.33 · DOI: 10.1021/es400334t · Source: PubMed

CITATIONS READS 6 73

# 7 AUTHORS, INCLUDING:



Roko Zaja University of Oxford

**49** PUBLICATIONS **589** CITATIONS

SEE PROFILE



Marta Popovic

University of Oxford

11 PUBLICATIONS 172 CITATIONS

SEE PROFILE



Ivan Senta

Ruđer Bošković Institute

20 PUBLICATIONS 379 CITATIONS

SEE PROFILE



Marijan Ahel

Ruđer Bošković Institute

108 PUBLICATIONS 3,890 CITATIONS

SEE PROFILE



Article

pubs.acs.org/est

# 1 Identification of P-Glycoprotein Inhibitors in Contaminated <sup>2</sup> Freshwater Sediments

- 3 Roko Zaja, Senka Terzić, Ivan Senta, Jovica Lončar, Marta Popović, Marijan Ahel, and Tvrtko Smital\*
- 4 Division for Marine and Environmental Research, Rudjer Boskovic Institute, Zagreb, Croatia
- Supporting Information

6

8

10

11

12

13

14

15

16


17

18

19

20

21 22 ABSTRACT: P-glycoprotein (P-gp, ABCB1) is an important part of the multixenobiotic resistance (MXR) defense system in aquatic organisms. The main goal of this study was identification of P-gp inhibitors in contaminated sediments using the effectdirected analysis (EDA) approach. The samples were collected from the Gorjak creek (Zagreb, Croatia), a recipient of wastewater effluents from the pharmaceutical industry. Sediment samples were extracted and fractionated using a two-tiered approach. Resulting nonpolar, medium polar, and polar fractions were tested on the inhibition of P-gp activity using P-gp overexpressing PLHC-1/dox cells and calcein-AM as model substrate. The obtained EC50 values (up to 757  $\mu$ g/g, expressed in toxicity equivalents of model P-gp inhibitor cyclosporine A) revealed high inhibitory potential of polar fractions of investigated sediments and clearly reflected the impact of pharmaceutical wastewater. P-gp specific ATPase assay and the cytotoxicity modulation experiments with colchicine indicated that most of the observed P-gp inhibition was due to the



presence of noncompetitive inhibitors. A detailed chemical analysis by ultrahigh-performance liquid chromatographyquadrupole/time-of-flight mass spectrometry (UPLC-QTOFMS) revealed nonionic surfactants, including alcohol polyethoxylates (LAEOs) and polypropylene glycols (PPGs), as the major components of the most active subfractions. Testing of several LAEO and PPG commercial mixtures confirmed their potential to inhibit the fish P-glycoprotein and modulate toxicity of other xenobiotics present in complex environmental samples.

#### INTRODUCTION

25 The outer cell membrane represents the first line of nonspecific 26 defense against xenobiotics. Efflux transport proteins within the 27 cell membrane provide this defense by actively extruding 28 xenobiotics out of the cells, preventing their accumulation inside 29 the cell and consequently reducing their toxic potential. Such 30 transporters were first described in human tumor cell lines and 31 related tissues as major factors in development of the multidrug 32 resistance (MDR) phenotype. Different mammalian models 33 indicate that several members from the large ABC (ATP-binding 34 cassette) family of proteins are major mediators involved in efflux 35 of various drugs and/or their metabolites. Through binding and 36 hydrolyzation of ATP, ABC proteins obtain energy for active 37 transport of their substrates across cell membranes. In mammals, 38 49 members of the ABC protein superfamily are subdivided into 39 seven families designated A through G (http://nutrigene.4t. 40 com/humanabc.htm). The ABCB1 (MDR, P-glycoprotein), 41 ABCG2 (breast cancer resistance protein, BCRP), and several 42 members from the ABCC (multidrug resistance associated 43 proteins, MRPs) family are directly involved in the efflux of 44 xenobiotics, representing toxicologically most relevant ABC 45 transport proteins.1

Because of its overexpression in various tumor tissues and cell 47 lines, the P-glycoprotein (P-gp; ABCB1) became the first and 48 best characterized ABC transporter. The initial observation that 49 many populations of aquatic organisms can survive in a highly 50 polluted environment triggered the first identification of the P-

gp-like efflux activity in aquatic organisms.<sup>2</sup> The related 51 phenomenon was soon termed the multixenobiotic resistance 52 mechanism (MXR), and the presence and function of P-gp 53 (ABCB1) has been identified in numerous aquatic organisms 54 investigated so far.<sup>3-5</sup> Similarly to its role in the MDR in 55 mammals, P-gp pumps many structurally different xenobiotics 56 out of the cells of aquatic organisms, reducing their cytotoxicity. 6 57 Furthermore, the induction of P-gp-like genes, proteins, and/or 58 transport activity has been shown in different tissues of fish and 59 mussels living in polluted environments.<sup>7–9</sup> Finally, it has been 60 demonstrated that specific classes of environmental compounds, 61 both of natural and anthropogenic origin, can lead to inhibition 62 of P-gp-like transport activity. <sup>10</sup> These P-gp inhibitors are called 63 chemosensitizers, because they can cause an increase in 64 sensitivity to other toxic compounds inside cells through 65 competitive or noncompetitive blockage of P-gp mediated 66 efflux.<sup>11</sup> Consequently, development of a methodological 67 framework for the detection and identification of potent P-gp 68 inhibitors in complex environmental samples is of ultimate 69 ecotoxicological importance.

Aquatic sediments are a major sink for a number of 71 anthropogenic pollutants. They contain highly complex mixtures 72

Received: January 22, 2013 Revised: April 5, 2013 Accepted: April 9, 2013






Figure 1. Schematic presentation of the extraction procedure used in the study.

73 of diverse pollutants, and their ecotoxicological prioritization 74 remains a challenging task, requiring a complex analytical 75 approach. Such procedures typically include combination of a 76 detailed sample fractionation and advanced chemical analytical 77 methods driven by biological effects. This, so-called effect-78 directed analysis (EDA) approach, has been successfully used in 79 identification and prioritization of pollutants, e.g., for the 80 identification of aryl hydrocarbon receptor (AhR) agonists, 81 estrogenic and androgenic compounds, and mutagenic com-82 pounds as well as the pollutants responsible for chronic toxicity 83 in various environmental matrices. 12–14

However, despite the potential ecotoxicological importance of 85 P-gp inhibitors, so far no EDA study has focused on the detection 86 and identification of this type of chemical in complex 87 environmental samples. One of the reasons is the lack of 88 appropriate in vitro models. Although the cell lines that 89 overexpress P-gp and other human xenobiotic transporters are 90 readily available, environmentally more relevant in vitro tools, 91 expressing transporters from aquatic organisms, have not been 92 developed. Our group previously described the expression of a 93 series of (eco)toxicologically relevant ABC transporters in the 94 PLHC-1 hepatoma cell line derived from topminnow 95 (Poeciliopsis lucida), one of the most frequently used in vitro 96 models in aquatic toxicology. Following that work, we selected and characterized the doxorubicin resistant PLHC-1 subclone (PLHC-1/dox), which exhibits high overexpression of fish P-99 gp. 15 Finally, together with the previously established calcein-AM 100 (Ca-AM) assay as a high throughput method for initial detection 101 of P-gp inhibitors, we recently optimized the P-gp specific 102 ATPase assay using the membrane vesicles isolated from PLHC-

1/dox cells, offering the first specific method that can be used to 103 reveal the type of interaction with fish P-gp. <sup>16</sup> Therefore, the 104 main goal of this study was an EDA-based detection and 105 identification of P-gp inhibitors in contaminated freshwater 106 sediments impacted by the pharmaceutical industry.

#### EXPERIMENTAL SECTION

**Study Site.** The sediment samples were collected in February 109 2008 at several locations along the Gorjak Creek, a small 110 watercourse in the area of the city of Zagreb, Croatia, highly 111 influenced by wastewater discharges from the nearby pharma- 112 ceutical and baker's yeast production facilities.<sup>17</sup> The sampling 113 design included a reference location, situated 500 m upstream 114 from the wastewater discharge point, and 5 locations situated 115 100–4000 m downstream from the discharge point (Figure S1 in 116 Supporting Information). Surface sediment samples (0-10 cm) 117 were collected using a plastic coring device and transferred to the 118 laboratory in Zagreb within 5 h. The wet sediment samples were 119 homogenized, and an aliquot of about 1 kg per sample was air- 120 dried at room temperature in a clean fume hood and then 121 pulverized using a mechanical mill. Ground sediment fractions, 122 having a particle size less than 63  $\mu$ m, were isolated by dry sieving 123 and stored at 4 °C until extraction.

Sediment Extraction and Fractionation. A complex 125 scheme including sample extraction and two levels of extract 126 fractionation was employed for the analysis of the collected 127 sediment samples (Figure 1). Briefly, subsamples of 50 g of dry 128 f1 sediment were extracted by Soxhlet extraction in two separate 129 cycles of 8 h each using methylene chloride (200 mL) and 130 methanol (200 mL) as extracting solvents. The resulting extracts 131

132 were combined and reduced to a small volume using rotary 133 evaporation followed by evaporation under nitrogen stream 134 using a TurboVap system (Caliper Life Sciences, Hopkinton, 135 MA, USA). The residue was transferred into 4 mL screw-cap 136 vials. Before further separation, 10% of the total (raw) extract was 137 taken from each sample and divided into two identical aliquots 138 for chemical and biological analyses. The remaining extracts were 139 subjected to an additional separation step using silica gel deactivated with 15% water. 18 The total extract was applied to the 141 top of the silica gel column (5 mL) and subsequently eluted with 142 25 mL of n-hexane, 30 mL of dichloromethane, and 30 mL of 143 methanol to yield nonpolar (A), medium-polar (B), and polar 144 fractions (C), respectively. Each of the fractions was reduced in 145 volume by evaporation under the N<sub>2</sub> stream and transferred into 146 1.8 mL vials fitted with Teflon-lined screw caps. A 10% aliquot was taken from each of the collected three silica gel fractions in 148 order to determine the relative distribution of P-gp inhibitors 149 among the fractions.

The remaining extract (80%) was subjected to a detailed 151 fractionation by preparative high-performance liquid chromatog-152 raphy (HPLC), using a Varian ProStar instrument, equipped 153 with an autosampler (Model 410), photodiode array detector (Model 330), and fraction collector (Model 704). The polar 155 fraction (C) was separated by preparative reverse-phase 156 chromatography using an octadecyl silica (C18) column (250 157 × 10 mm) (Phenomenex, Torrance, USA), applying a binary gradient at a mobile-phase flow of 5 mL/min. The mobile phase 159 A was a mixture of water and acetonitrile (8/2), and the mobile phase B was pure acetonitrile. The following gradient elution was 161 applied: 0−5 min, 100% A; 5−10 min, the percentage of B 162 linearly increased from 0 to 25%; 10-25 min, the percentage of B 163 linearly increased from 25 to 100%; 25-40 min, isocratic hold at 164 100% B. The separate fractions were collected in uniform time 165 intervals of 1 min. The fractions, obtained after HPLC 166 fractionation, were divided into 2 identical aliquots for further 167 chemical and bioassay analyses. All aliquots for biological 168 analyses were evaporated to dryness, dissolved in dimethlysulph-169 oxide (DMSO), and stored at 4 °C until further analyses.

Chemical Analysis. The applied analytical protocol was designed to provide a comprehensive characterization of the prepared extracts, covering a wide range of possible nontarget and target contaminants as described in our previous publications. The most polar silica gel fraction and subfractions from the C<sub>18</sub>-HPLC fractionation were analyzed by liquid chromatography/time-of-flight mass spectrometry (LC/QTOF MS). The details on LC/QTOF MS technique, applied in the study, can be found in the Supporting Information. The identifications of nontarget compounds by ultrahigh-performance liquid chromatography (UPLC)/QTOF were performed on the basis of accurate mass determination and chromatographic information as described earlier. In addition, the extracts were checked for the presence of a number of suspected target contaminants.

Growth and Treatment of PLHC-1/wt and PLHC-1/dox 186 Cells. PLHC-1 (*Poeciliopsis lucida* hepatocellular carcinoma) 187 cells were obtained from the American Type Culture Collection 188 (ATCC; LGC Promochem, Teddington, UK). PLHC-1/dox cell 189 line was previously isolated and characterized in our laboratory. 15 190 The cells were grown at 30 °C in DMEM/F12 medium 191 containing L-glutamine and 5% FBS.

Treatment of PLHC-1/dox Cells: Calcein-AM Assay, 193 Membrane Vesicles Isolation, and the ATPase Assay. 194 Transport activity of P-gp was measured using the Ca-AM assay

as previously described, 21 with slight modifications (described in 195 more detail in Supporting Information). Calcein fluorescence 196 was finally measured using a microplate reader (Infinite M200, 197 Tecan, Salzburg, Austria) at 485 nm excitation and 530 nm 198 emission wavelengths. For the purpose of membrane vesicles 199 preparation, PLHC-1/wt and dox cells were cultured in 175 cm<sup>2</sup> 200 culture flasks till confluence and then scraped and centrifuged. 201 The resulting pellet was frozen at -80 °C until further use. 202 Plasma membrane vesicles were then isolated as described by 203 Cornwell et al.<sup>22</sup> The pellet containing plasma membrane 204 vesicles was resuspended in 0.5 mL of sample buffer, and total 205 proteins were determined by the Lowry method.<sup>23</sup> ATPase 206 activity was measured using the malachite green method with 207 modifications. 16,24 The amount of the released inorganic 208 phosphate was finally spectrophotometrically measured using a 209 microplate reader at 625 nm. The release of inorganic phosphate 210 was also measured in the presence of 1.2 mM orthovanadate to 211 determine the vanadate sensitive fraction of the ATPase reaction. 212

**Cytotoxicity Determinations and Cytotoxicity Modu-** 213 **lation Experiments.** Cytotoxicity was determined using 214 PLHC-1/dox cells by the MTT reduction assay adapted 215 according to the Mosmann's procedure. The formazan salts 216 were finally dissolved in isopropanol, and the plates were read 217 using a microplate reader at 570 nm using 750 nm as a reference 218 wavelength. Additional details are described in the Supporting 219 Information.

**Data Analysis.** In the case of the calcein-AM and MTT assay, 221 EC50 (MTT) or IC50 (Ca-AM) values were calculated using a 222 classical sigmoidal four parameters dose—response model: 223

$$y = b + (a - b)/(1 + 10^{((\log EC50 - x) * h)})$$

where y is the response, b represents the minimum of response, a 224 represents the maximum of response, h is the shape parameter, 225 and x is the logarithm of inhibitor concentration. IC50 values 226 denote concentrations that resulted in 50% of maximal increase 227 in Ca-AM accumulation over the control cells treated with Ca- 228 AM only, obtained upon addition of model P-gp inhibitor 229 cyclosporine A (7.5  $\mu$ M). EC50 value is the concentration of 230 substance or sample that corresponds to 50% of maximal 231 cytotoxic effect. The potency of samples to reverse the colchicine 232 resistance of PLHC-1/dox cells was expressed as the modulation 233 factor (MF) and calculated according to the equation:

$$MF (\%) = (EC50_{PLHC-1/dox} - EC50-IN_{PLHC-1/dox})$$
$$/(EC50_{PLHC-1/dox} - EC50_{PLHC-1/wt}) \cdot 100$$

where EC50 $_{PLHC-1/dox}$  and EC50 $_{PLHC-1/wt}$  are EC50 values of 235 specific drugs obtained for PLHC-1/dox and PLHC-1/wt cells, 236 respectively. EC50-IN $_{PLHC-1/dox}$  is the EC50 of drug obtained 237 with PLHC-1/dox cells in the presence of specific transport 238 inhibitor (cytotoxicity modulator).

Cyclosporine A toxicity equivalents (CYC-FEL TEQ) were 240 calculated as proposed by Brack et al. 26 using the fixed effect level 241 approach. Ca-AM accumulation caused by sediments was related 242 to IC20 values of cyclosporine A. All experiments were 243 independently repeated 3–5 times. All calculations were 244 preformed using R version 2.15.0 and Gnumeric Spreadsheet 245 for Ubuntu-Linux 10.04.

#### RESULTS AND DISCUSSION

P-gp Inhibitory Potential of Contaminated Sediments. 248 Using the Ca-AM efflux assay as a fast and reliable screening 249

247




Figure 2. P-gp inhibitory potential of the Gorjak creek sediment samples as determined by the calcein-AM assay with PLHC-1/dox cells. Presented are results of the initial screening of nonfractioned sediment samples (black bars), inhibitory potential of major S1 fractions (gray bars; B-medium polar and C-polar fraction), along with the summed effect of the major S1 fractions (A + B + C) and summed effect of the S1–C polar subfractions (S1-C1 to C-40) (open bars). P-gp inhibitory effect of the nonpolar fraction A was below detection limit of the method. Asterisks denote statistically significant differences in comparison to the P-gp inhibitory effect of the sediment sample collected at the location S0 before the production facilities, at P < 0.05 (\*), 0.01 (\*\*\*), or 0.001 (\*\*\*). Results are expressed in toxic equivalents of model P-gp inhibitor cyclosporine A (CYC-FEL TEQ,  $\mu$ g/g of dry sediment) and are means  $\pm$  SDs (n = 3).

Table 1. List of the Major Contaminant Classes Identified in the Polar (S1-C) Fraction of the Contaminated Sediment from the Gorjak Creek

compound name	abbrev	type of compound/origin	estimated concentration $(\mu g/g)$		
polypropylene glycols	PPG	solvent, nonionic surfactant	120		
alcohol polyethoxylates	$A_{13}EO_n$	nonionic surfactants	3		
alkyldimethylbenzylammonium (chloride)	ADBAC	cationic surfactants	39		
linear alkylbenzene sulfonates	LAS	anionic surfactants	65		
azythromycin	AZI	macrolide	8.5 <sup>a</sup>		
erythromycin	ERY	macrolide	$0.8^{a}$		
desmethylazithromycin	DAZI	macrolide intermediate	$8.8^a$		
dehydroerythromycin	ERY-H <sub>2</sub> O	ERY transformation product	3.3 <sup>a</sup>		
zolpidem	ZOL	psychiatric drug	5.0 <sup>a</sup>		
torsemide	TOR	diuretic	8.2 <sup>a</sup>		
terbinafine	TER	antifungal drug	2.8 <sup>a</sup>		
chlortalidone	CHL	diuretic	20.1 <sup>a</sup>		
warfarin	WAR	anticoagulant	1.4		
ata from the ref 19.					

250 method, a high potential of all analyzed sediment samples to 251 interact with the fish P-gp transport activity was observed (Figure 2; Table S1 in Supporting Information). Sediment sample collected at the reference location S0 situated 500 m upstream from the major source of pollution also showed the presence of -gp inhibitors, but the inhibitory potential was almost 20 times lower than in the S1 sample collected immediately downstream from the pharmaceutical facility. Locations further downstream from the S1 site exhibited a gradual decrease in concentrations of -gp inhibitors, in accordance with the expected pollution gradient. The concentration of P-gp inhibitors, expressed in 260 CYC-FEL TEQ, at the most downstream location (S19) was 261 13.6  $\mu$ g/g, which was very close to the value obtained for the reference location S0. 263

Initial fractionation of the reference sediment extract S0 and the extracts that showed the highest inhibitory potential (S1 and S5) on a silica gel column resulted in three subfractions having different polarities. In all fractionated samples, P-gp inhibitors were almost exclusively associated with the most polar fraction C (Figure 2; Table S1 in Supporting Information). The medium

polar fraction (S1-B) showed a measurable inhibitory potential 270 only in the most polluted S1 sample. For the majority of the 271 samples, cumulative effects, calculated as the sum of the 272 individual inhibitory effects of the three major subfractions, 273 were almost identical to the effect of composite samples. The 274 only exception was the most polluted sample S1, for which the 275 summed subfractions S1-C and S1-B resulted in 757  $\mu$ g/g of 276 CYC-FEL TEQ, while the nonfractionated S1 sample contained 277 only 364  $\mu$ g/g of toxic equivalents (Figure 2). This discrepancy 278 could be explained by the presence of some unknown toxicants in 279 the composite sample S1, which were in the next step separated 280 by the silica gel fractionation, resulting in higher P-gp inhibitory 281 potential of the S1-C sample. Namely, the applied Ca-AM assay 282 is based on the cleavage of Ca-AM by nonspecific esterases inside 283 the cell, resulting in the release of fluorescent calcein. However, 284 esterases were shown to be highly sensitive to inhibition by toxic 285 compounds, masking the potential effects on P-gp transport 286 activity.<sup>27</sup> In order to test this hypothesis, we performed 287 additional tests: rhodamine 123 (Rh123) assay and the esterases 288 inhibition assay using the cytosolic preparation of PLHC-1 cells. 289




Figure 3. P-gp inhibitory potential of the S-1C individual subfractions and their relative contribution to the overall inhibitory potency of the S1-C fraction. Inhibitory potential of subfractions was determined by the calcein-AM assay with PLHC-1/dox cells and expressed in  $\mu$ g/g CYC-FEL TEQ. Relative contributions of subfractions were calculated and expressed with respect to the toxicity of the major S-1C fraction set at 100%.

290 Although Rh123 is less responsive as a P-gp probe in comparison to Ca-AM, it is not sensitive to esterases inhibition. Indeed, data 292 using Rh123 as a model P-gp supstrate showed the highest 293 inhibitory effect of nonfractionated S1 sample in comparison to 294 the effect of major A—B—C fractions, and our results confirmed 295 much higher esterases inhibitory effect of the composite S1 296 sample in comparison with the S1-C fraction (Figure S4 and 297 Table S5 in Supporting Information). Despite this potential 298 drawback, however, the Ca-AM efflux assay still represents the 299 method of choice due to its higher response, simplicity, and high 300 throughput potential. Nevertheless, in order to avoid under-301 estimation of inhibitory potential, it is highly recommended to 302 test the sample for its ability to inhibit esterases, especially when 303 testing complex environmental samples of unknown chemical 304 composition.


In further attempt to identify chemicals causing the observed 305 306 P-gp inhibition, the polar fraction of the S1 sample was characterized in depth using the UPLC/QTOF technique.<sup>20</sup> The main classes of compounds found in the sample are listed in Table 1. As can be seen, the sample contained significant concentrations of different contaminant classes, including pharmaceutical compounds as well as complex assemblage of various anionic, nonionic, and cationic surfactants. Pharmaceuticals included macrolide antibiotics and their intermediates, diuretics torsemide and chlorthalidone, anticoagulant warfarin, antifungal drug terbinafine, and psychiatric drug zolpidem. The estimated concentrations of these pharmaceutical compounds at the most polluted location were in the range from 1 to 20 mg/kg. On the other hand, the concentration levels of surfactants were estimated to be even higher (up to 100 mg/kg), in particular linear alkylbenzene sulfonates (LAS), polypropylene glycols (PPG), and alkyldimetylbenzylammonium cationic surfactants (ADBACs). It should be noted that the enhanced presence of polypropylene glycols (PPGs) and ADBACs indicates predominately pharmaceutical origin of surfactants. PPGs are widely used in the pharmaceutical industry as inactive solvents of active drug ingredients, while ADBACs find their application as disinfectants in various formulations.

On the basis of the results achieved using simple silica gel fractionation, we focused our further research on a more detailed analysis of the C subfraction of the S1 sample, with an attempt to identify the most potent P-gp inhibitors in the sediment extract. The fraction S1-C was HPLC-fractionated into 40 subfractions

(S1-C1 to S1-C40), and the fractions were subsequently tested 333 for their inhibitory potential. The sum of CYC-FEL TEQ values 334 for all individual subfractions (S1-C1 to C40) was 569  $\mu$ g/g, 335 corresponding to 85% of the total activity found in the composite 336 S1-C fraction (672  $\mu$ g/g of CYC-FEL TEQ; Figure 2 and Table 337 S1 in Supporting Information). This indicated that some of the 338 active substances, presumably belonging to the highly lipophilic 339 compounds in terms of C<sub>18</sub> HPLC elution, were lost during the 340 fractionation step. It should be pointed out that the first 18 S1-C 341 subfractions did not show any detectable effect on P-gp transport 342 activity (Figure 3). The majority of other fractions showed 343 f3 measurable inhibitory potential, but most of the P-gp inhibition 344 was associated with the fraction S1-C30. This fraction contained 345 367  $\mu$ g/g CYC-FEL TEQ, which explained 65% of the total 346 inhibitory effect observed in the S1-C fraction. Consequently, in 347 the next step of our study, we performed a detailed chemical and 348 biological analysis of the S1-C30 subfraction.

Chemical Identification of Contaminants in S1-C30 350 Fraction. The most potent fraction S1-C30 was characterized in 351 detail by the UPLC/QTOF technique in order to get closer to 352 the chemical identity of the substances causing the observed P-gp 353 inhibitory effect. The UPLC chromatogram of this fraction is 354 shown in Figure 4A. It contained several resolved peaks, and we 355 f4 were able to identify most of them, as shown in Table 2. Most of 356 t2 the peaks belonged to either nonionic or cationic surfactants, 357 including dialkyldimethylammonim and alkyldimetylbenzylam- 358 monium cationic surfactants, as well as tridecanol polyethoxylate 359 and PPG nonionic surfactants. The largest peak at 11.4 min was 360 the PPG oligomer with 18 PEO units (PPG18). The mass 361 spectrum of this compound, presented in Figure 4B, shows 362 characteristic adducts of PPG18 with the sodium and ammonium 363 ions, leading to the dominant singly charged ion  $[M + Na]^+$  at  $m/_{364}$ z 1085.7607 and doubly charged ion  $[M + 2H]^{2+}$  at m/z 365 532.3829. Other minor ions, present in the chromatogram, were 366 formed by a subsequent loss of propoxy unit (C<sub>3</sub>H<sub>6</sub>O) from the 367 protonated PPG18 molecule.

Another dominant component of this fraction (RT 12.8 min)  $_{369}$  was nonionic surfactant tridecanol polyethoxylate ( $C_{13}EO_n$ ) with  $_{370}$  an average number of EO units of about 6. Furthermore, all  $_{371}$  ethoxymers of this commercial mixture were eluted under the  $_{372}$  same broad peak, which can be seen in the mass spectrum,  $_{373}$  displaying a characteristic pattern of  $[M + H]^+$  ions of individual  $_{374}$  ethoxymers with a mass difference of 44 Da (Figure 4C). Apart  $_{375}$ 



**Figure 4.** Analytical chemical identification of the major constituents of the fraction S1-C30. (A) UPLC/TOF MS chromatogram of the fraction S1-C30, (B) accurate mass spectrum of the peak at 11.6 min, which was identified as polypropyleneglycol with 18 PO units (PPG 18), and (C) accurate mass spectrum of the peak at 12.8 min, which was identified as tridecanol polyethoxylate with an average number of EO groups of 6.


Table 2. Major Contaminants Identified in the Most Active Fraction S1-C30 of the Sediment Extract from the Gorjak Creek

RT/ min	m/z	elemental composition	$\begin{array}{c} \text{mass accuracy/} \\ \Delta \text{ mDa} \end{array}$	compound name; origin
9.65	242.2825	$C_{16}H_{36}N [M]^+$	-2.3	tetrabutylammonium; cationic surfactant
10.96	270.3138	$C_{18}H_{40}[M]^+$	-2.3	dioctyldimethylammonium; cationic surfactant
11.41	1063.7760	$C_{54}H_{111}O_{19}[M+H]^+$	+4.0	polypropyleneglycol (PPG), nPO = 18; nonionic surfactant; solvent
12.80	465.3773	$C_{25}H_{53}O_7 [M + H]^+$	-1.8	tridecanol polyethoxylate; $C_{13}EO_{3-8}$ (the $m/z$ value is given for the most abundant oligomer $C_{13}EO_6$ ); nonionic surfactant
13.30	360.3612	$C_{25}H_{46}N [M]^+$	-1.8	hexadecyldimethylbenzylammonium; cationic surfactant; antiseptic
13.51	312.3607	$C_{21}H_{46}N[M]^{+}$	-2.3	octadecyltrimethylammonium; cationic surfactant
14.81	388.3919	$C_{27}H_{50}N [M]^+$	-2.4	octadecyldimethylbenzylammonium; cationic surfactant; antiseptic

376 from nonionic surfactants, several cationic surfactants were also 377 identified in the S1-C30 fraction. These included dioctyldime-378 thylammonium (RT 10.96 min) and octadecyldimethylbenzylammonium (RT 14.8 min) quarternary ions. Mass spectra of the 379 identified compounds are given in Supporting Information 380 (Figure S2). None of the prominent pharmaceutical compounds, 381

382 identified in the sediment extract and listed in Table 1, was found 383 in the P-gp active fractions. The analysis of the S1-C30 fraction 384 indicated possible importance of surfactants as potent P-gp 385 inhibitors, and in the final step of our study, we performed an 386 extensive testing of a number of commercial mixtures of nonionic 387 and cationic surfactants.

P-gp Inhibition Potency of Surfactants. We tested a series of cationic and nonionic surfactants (Table S4 in Supporting Information), structurally similar to those found in the sediment samples, for their potential to inhibit P-gp activity. As can be seen in Figure 5, none of the cationic surfactants tested showed any P-



**Figure 5.** Determination of the P-gp inhibitory potential of commercially available mixtures of cationic and nonionic surfactants structurally similar to those found in the S-1C subfraction #30. Inhibitory potential of surfactants (nominal concentrations ( $\mu$ M) given in parentheses, abbreviations according to the list presented in Table S4 in Supporting Information) was determined by the calcein-AM assay with PLHC-1/dox cells and expressed in % of the maximal effect observed with model P-gp inhibitor cyclosporine A (7.5  $\mu$ M) set at 100%. Data are means  $\pm$  SDs (n = 3).

393 gp inhibitory potential, in accordance with previously reported 394 results for the mammalian P-gp. <sup>28,29</sup> On the contrary, most of the 395 nonionic surfactants showed a highly significant P-gp inhibitory

potential, ranging from 30% to 70% of the maximal inhibition 396 observed with cyclosporine A as a model P-gp inhibitor (Figure 397 5). Among nonionic surfactants, we tested structurally different 398 alcohol polyethoxylates, which showed a significant variability in 399 their specific inhibitory effects, depending on the structure of 400 their alkyl and polyethoxylate moiety, respectively. Higher 401 responses were obtained for commercial mixtures having average 402 alkyl chain length of about 12 (Genapol L series), while mixtures 403 with larger chain lengths (C16–C18; Genapol T series) gave 404 lower responses. IC50 values for the most active Genapols LA-405 030 and LA-070 were 2.1 and 1.2  $\mu$ M, respectively (Table S4 in 406 Supporting Information).

These observations are in agreement with the study published 408 by Seelig and Gerebtzoff,<sup>30</sup> which showed that polyethoxylate 409 surfactants interact with human P-gp in the concentration range 410 that does not disorder cell membrane. Furthermore, it has been 411 demonstrated that the degree of interaction with human P-gp 412 depends on both the length of the alkyl chain and the number of 413 ethoxy groups in the molecule.<sup>31</sup> Alkyl chain represents the 414 hydrophobic part of the molecule that enables its partition in the 415 lipid membrane, the first and prerequisite step for interaction 416 with P-gp. In the second step, the polyethoxylate part of the 417 molecule enters the transporter active site through the lateral 418 cleft in the P-gp molecule oriented toward the membrane 419 bilayer.<sup>32</sup> Once inside the P-gp cavity, polyethoxylate groups 420 form the multiple hydrogen bonds within the active site of the 421 transporter. The fine balance between the number of ethoxy 422 groups and length of alkyl chain is of crucial importance for 423 degree and type of interaction with P-gp, and it has been shown 424 that the oligomer having 12 carbon atoms in the alkyl chain and 8 425 ethoxy groups showed the strongest interaction with the human 426 P-gp transporter.<sup>33</sup> The predominant type of alcohol polyethox- 427 ylates in the S1-C30 fraction identified by UPLC/QTOF analysis 428 was C<sub>13</sub>EO<sub>6</sub>, which has a very similar hydrophilic-lipophilic 429 balance like C<sub>12</sub>EO<sub>8</sub>.

Apart from alcohol polyethoxylate type of nonionic 431 surfactants, the UPLC/QTOF analysis revealed high concen- 432 tration of the PPG oligomer with 18 PEO units. Therefore, we 433 tested three PPGs with varying average number of PEO units of 7 434 (PPG 425), 12 (PPG 725), and 17 (PPG 1000). High inhibitory 435




Figure 6. Identification of the type of P-gp inhibitory potential of tested Gorjak Creek sediment extracts using the fish P-gp ATPase assay. (A) Effects of the raw sediment extracts, verapamil (model P-gp ATPase competitive inhibitor) or cyclosporine A (model noncompetitive inhibitor); (B) effects of the extract of the S1 sediment sample and corresponding nonpolar (S1-A), medium polar (S1-B), and polar (S1-C) fractions. Blank denotes procedural control. Results are expressed as percentage of the baseline P-gp ATPase activity set to 100%. The values represent means  $\pm$  SDs (n = 3).

516

525

526

532

533

537

436 potential, reaching almost 70% of the maximal inhibition 437 observed with cyclosporine A (7.5  $\mu$ M), was determined for 438 PPG 725 and PPG 1000 (Figure 5), while the inhibitory potential 439 of PPG 425 was significantly lower. However, it should be noted 440 that, despite the high maximal inhibition observed for PPGs, 441 their relative affinities values were significantly lower (higher 442 IC50 values) than in the case of Genapols (Table S4 in 443 Supporting Information).

Type of the Identified P-gp Inhibitors. Although the Ca-445 AM assay offers a sensitive and high throughput tool for the 446 detection of the P-gp inhibitory potential, it does not provide any 447 information on the type of P-gp inhibitors present in analyzed samples; i.e., it is not possible to discern between the chemical inhibitors that block the transport activity by competition for substrate binding site(s) and substances that noncompetitively 451 inhibit the P-gp transport, e.g., by blocking the ATP hydrolysis or 452 by some other nonspecific mechanisms. To overcome this 453 drawback, we used the fish P-gp ATPase assay recently optimized 454 by our group. 16 None of the analyzed samples showed any 455 activation of the ATPase activity in the wide range of tested 456 concentrations (data not shown). However, all of the initial (nonfractionated) samples exhibited inhibition of the P-gp 458 ATPase activity, with S1 being the most potent sample (Figure 459 6A), in agreement with data obtained using the Ca-AM assay 460 (Figure 2). In addition, the results also indicated the 461 predominant presence of noncompetitive inhibitors in the 462 analyzed samples. Furthermore, inhibition of ATPase activity was almost completely associated with the polar fraction S1-C 464 (Figure 6B), which is again in accordance with the results 465 obtained by the Ca-AM assay. The same pattern, showing 466 predominant association of P-gp inhibitors with the polar 467 fraction, was observed in all other samples (not shown). In 468 addition, using the MTT modulation assay, we confirmed that 469 the predominant type of inhibitors present in S1-C sample are 470 noncompetitive inhibitors. Addition of the S1-C sample 471 modulated the cytotoxicity of the model P-gp substrate 472 colchicine in a concentration-dependent manner, while no 473 cytotoxicity modulation of the S1-C sample was observed in the 474 presence of the model MRP (ABCC) inhibitor MK571 (Table 475 S3 and Figure S3 in Supporting Information). Recent studies on 476 human P-gp using the ATPase assay showed that nonionic 477 surfactants can behave either like substrates or noncompetitive inhibitors of the transport activity, depending predominantly on 479 the character of the hydrophobic part of the molecule, i.e., on the 480 type and length of the alkyl chain.<sup>33</sup> It was shown that the 481 increase in the alkyl chain length from 6 to 14 resulted in a 482 general tendency of decreasing stimulating effect and increasing 483 inhibitory effect on P-gp related ATPase activity. Our findings 484 that tested alcohol polyethoxylates (C12-C16 alkyl chain), as 485 well the as the alcohol polyethoxylates present in the S1-C30 486 fraction (C13 alkyl chains), behaving as noncompetitive 487 inhibitors, are in accordance with the described findings for 488 human P-gp.

489 **Ecotoxicological Relevance of P-gp Inhibition by**490 **Nonionic Surfactants.** Surfactants are high production volume
491 chemicals, 34 which enter the aquatic environment in significant
492 quantities despite the fact that most of the common surfactant
493 types are readily biodegradable during the conventional
494 wastewater treatment. 35 Approximately 50% of the total
495 surfactant production belongs to the nonionic surfactants. 34
496 The first observations, suggesting that nonionic surfactants can
497 modulate the activity of human P-gp, were reported back in the
498 1990s, but only recent studies showed that these compounds can

act as specific substrates or inhibitors of P-gp at the 499 concentrations much lower than those needed for disordering 500 of the cell membrane. Our study is the first report, which 501 identified nonionic surfactants of the alcohol polyethoxylate type 502 and polypropylene glycols as potent inhibitors of the fish P-gp 503 activity. Moreover, we found that these nonionic surfactants were 504 major constituents of a contaminated sediment extract, 505 exhibiting strong fish P-gp inhibitory potency. Consequently, 506 although surfactants are generally considered only weakly to 507 moderately toxic at the concentrations typically found the 508 aquatic environment, 35,36 the results from this study reveal their 509 potential to modulate the toxicity of other xenobiotics by 510 inhibiting efflux activity of the fish P-glycoprotein, a critical 511 component of the cellular defense machinery in aquatic 512 organisms. Therefore, our results indicate the need for a careful 513 reassessment of the ecotoxicological relevance of these 514 ubiquitous environmental contaminants.

#### ASSOCIATED CONTENT

# Supporting Information

Additional information, including data on chemicals used in the 518 study, methodological details on LC/MS and biological analyses, 519 map of the study site, data on calcein-AM and Rh123 assays, 520 modulation of toxicity assays for tested sediment extracts and 521 commercial mixtures of nonionic and cationic surfactants, and 522 esterases inhibition data. This material is available free of charge 523 via the Internet at http://pubs.acs.org.

## AUTHOR INFORMATION

# **Corresponding Author**

\*Address: Laboratory for Molecular Ecotoxicology, Division for 527 Marine and Environmental Research, Rudjer Boskovic Institute, 528 Bijenička 54, 10 000 Zagreb, Croatia; tel: 385 1 45 61 088; fax: 529 385 1 46 80 243; e-mail: smital@irb.hr.

lotes 531

The authors declare no competing financial interest.

## ACKNOWLEDGMENTS

This work has been supported by the Ministry of Science, 534 Education and Sports of the Republic of Croatia, Project Nos. 535 098-0982934-2745 and 098-0982934-2712.

#### REFERENCES

- (1) Leslie, E. M.; Deeley, R. G.; Cole, S. P. C. Multidrug resistance 538 proteins: Role of Pglycoprotein, MRP1, MRP2, and BCRP (ABCG2) in 539 tissue defense. *Toxicol. Appl. Pharmacol.* **2005**, 204, 216–237.
- (2) Kurelec, B.; Pivcevic, B. Evidence for a multixenobiotic resistance 541 mechanism in the mussel *Mytilus galloprovincialis*. *Aquat. Toxicol.* **1991**, 542 19. 291–301.
- (3) Kurelec, B. The multixenobiotic resistance mechanisms in aquatic 544 organisms. *Crit. Rev. Toxicol.* **1992**, 22, 23–43.
- (4) Bard, S. M. Multixenobiotic resistance as a cellular defense 546 mechanism in aquatic organisms. *Aquat. Toxicol.* **2000**, 48, 357–389. 547
- (5) Sturm, A.; Segner, H. P-glycoproteins and xenobiotic efflux 548 transport in fish. In *Biochemistry and Molecular Biology of Fishes Vol. VI.* 549 *Environmental Toxicology*; Mommsen, T. P., Moon, T. W., Eds; Elsevier: 550 Amsterdam, 2005; pp 496–533.
- (6) Epel, D.; Luckenbach, T.; Stevenson, C. N.; Macmanus-Spencer, L. 552 A.; Hamdoun, A.; Smital, T. Efflux transporters: Newly appreciated roles 553 in protection against pollutants. *Environ. Sci. Technol.* **2008**, *42*, 3914 554 20.
- (7) Smital, T.; Sauerbor, R.; Hackenberger, B. K. Inducibility of the P- 556 glycoprotein transport activity in the marine mussel Mytilus 557

- 558 galloprovincialis and the freshwater mussel Dreissena polymorpha. 559 Aquat. Toxicol. 2003, 65, 443–465.
- (8) Tutundjian, R.; Cachot, J.; Leboulenger, F.; Minier, C. Genetic and immunological characterisation of multixenobiotic resistance system in the turbot (Scophthalamus maximus). *Comp. Biochem. Physiol., Part B* 2002, 132, 463–471.
- 564 (9) Williams, T. D.; Gensberg, K.; Minchin, S. D.; Chipman, J. K. A 565 DNA expression array to detect toxic stress response in European 566 flounder (*Platichthys flesus*). *Aquat. Toxicol.* **2003**, 65, 141–157.
- 567 (10) Smital, T.; Luckenbach, T.; Sauerborn, R.; Hamdoun, A. M.; 568 Vega, R. L.; Epel, D. Emerging contaminants Pesticides, PPCPs, 569 microbial degradation products and natural substances as inhibitors of 570 multixenobiotic defense in aquatic organisms. *Mutat. Res., Fundam. Mol.* 571 *Mech. Mutagen.* 2004, 552, 101–117.
- 572 (11) Smital, T.; Kurelec, B. The chemosensitizers of multixenobiotic 573 resistance mechanism in aquatic invertebrates: A new class of pollutants. 574 *Mutat. Res., Fundam. Mol. Mech. Mutagen.* **1998**, 399, 43–53.
- 575 (12) Keiter, S.; Grund, S.; van Bavel, B.; Hagberg, J.; Engwall, M.; 576 Kammann, U.; Klempt, M.; Manz, W.; Olsman, H.; Braunbeck, T.; 577 Hollert, H. Activities and identification of aryl hydrocarbon receptor 578 agonists in sediments from the Danube river. *Anal. Bioanal. Chem.* **2008**, 579 390, 2009–2019.
- 580 (13) Thomas, K. V.; Langford, K.; Petersen, K.; Smith, A. J.; Tollefsen, 581 K. E. Effect-directed identification of naphthenic acids as important in 582 vitro xeno-estrogens and anti-androgens in North Sea offshore 583 produced water discharges. *Environ. Sci. Technol.* **2008**, 43, 8066–8071. 584 (14) Brack, W. Effect-directed analysis: A promising tool for the 585 identification of organic toxicants in complex mixtures? *Anal. Bioanal.* 586 *Chem.* **2003**, 377, 397–407.
- 587 (15) Zaja, R.; Caminada, D.; Loncar, J.; Fent, K.; Smital, T. 588 Development and characterization of P-glycoprotein 1 (P-gp1, 589 ABCB1)-mediated doxorubicin-resistant PLHC-1 hepatoma fish cell 590 line. *Toxicol. Appl. Pharmacol.* **2008**, 227, 207–18.
- 591 (16) Zaja, R.; Loncar, J.; Popovic, M.; Smital, T. First characterization 592 of fish P-glycoprotein (abcb1) substrate specificity using determinations 593 of its ATPase activity and calcein-AM assay with PLHC-1/dox cell line. 594 *Aquat. Toxicol.* **2011**, *103*, 52–63.
- 595 (17) Terzic, S.; Mikac, I.; Senta, I.; Ahel, M. Comprehensive molecular 596 characterization of organic contaminants in freshwater sediments by gas 597 chromatography/mass spectrometry and liquid chromatography/time-598 of-flight mass spectrometry. In *Progress in Environmental Science and* 599 *Technology*; Li, S., Wang, Y., Cao, F., Huang, P., Zhang, Y., Eds.; Science 600 Press: Beijing, China, 2009; Vol. *II*, Part A, pp 397–405.
- 601 (18) Smital, T.; Terzic, S.; Zaja, R.; Senta, I.; Pivcevic, B.; Popovic, M.; 602 Mikac, I.; Tollefsen, K. E.; Thomas, K. V.; Ahel, M. Assessment of 603 toxicological profiles of the municipal wastewater effluents using 604 chemical analyses and bioassays. *Ecotoxicol. Environ. Saf.* 2011, 74, 605 844–851.
- 606 (19) Smital, T.; Terzić, S.; Lončar, J.; Senta, I.; Žaja, R.; Popović, M.; 607 Mikac, I.; Tollefsen, K. E.; Thomas, K. V.; Ahel, M. Prioritisation of 608 organic contaminants in a river basin using chemical analyses and 609 bioassays. *Environ. Sci. Pollut. Res.* **2012**, DOI: 10.1007/s11356-012-610 1059-x.
- 611 (20) Terzic, S.; Ahel, M. Nontarget analysis of polar contaminants in 612 freshwater sediments influenced by pharmaceutical industry using ultra-613 high-pressure liquid chromatography-quadrupole time-of-flight mass 614 spectrometry. *Environ. Pollut.* **2011**, *159*, 557–566.
- 615 (21) Zaja, R.; Klobucar, R. S.; Smital, T. Detection and functional 616 characterization of Pgp1 (ABCB1) and MRP3 (ABCC3) efflux 617 transporters in the PLHC-1 fish hepatoma cell line. *Aquat. Toxicol.* 618 **2007**, 81, 365–76.
- 619 (22) Cornwell, M. M.; Safa, A. R.; Felsted, R. L.; Gottesman, M. M.; 620 Pastan, I. Membrane vesicles from multidrug-resistant human cancer 621 cells contain a specific 150- to 170-kDa protein detected by photoaffinity 622 labeling. *Proc. Natl. Acad. Sci. U.S.A.* 1956, 83, 3847–3850.
- 623 (23) Lowry, O. H.; Rosebrough, N. J.; Farr, A. L.; Randall, R. J. Protein 624 measurement with folin phenol reagent. *J. Biol. Chem.* **1951**, 193, 265–625 275.

- (24) Henkel, R. D.; VandeBerg, J. L.; Walsh, R. A. A microassay for 626 ATPase. *Anal. Biochem.* **1998**, *169*, 312–318.
- (25) Mosmann, T. Rapid colorimetric assay for cellular growth and 628 survival: Application to proliferation and cytotoxicity assays. *J. Immunol.* 629 *Methods* 1983, 65, 55–63.
- (26) Brack, W.; Segner, H.; Moder, M.; Schuurmann, G. Fixed-effect- 631 level toxicity equivalents A suitable parameter for assessing 632 ethoxyresorufin-O-deethylase induction potency in complex environ- 633 mental samples. *Environ. Toxicol. Chem.* **2000**, *19*, 2493–2501. 634
- (27) Hollo, Z.; Homolya, L.; Davis, C. W.; Sarkadi, B. Calcein 635 accumulation as a fluorometric functional assay of the multidrug 636 transporter. *Biochim. Biophys. Acta, Biomembr.* **1994**, 1191, 384–388. 637
- (28) Batrakova, E. V.; Li, S.; Alakhov, V. Y.; Miller, D. W.; Kabanov, A. 638 V. Optimal structure requirements for pluronic block copolymers in 639 modifying P-glycoprotein drug efflux transporter activity in bovine brain 640 microvessel endothelial cells. *J. Pharmacol. Exp. Ther.* **2003**, 304, 845—641 854.
- (29) Shono, Y.; Nishihara, H.; Matsuda, Y.; Furukawa, S.; Okada, N.; 643 Fujita, T.; Yamamoto, A. Modulation of intestinal P-glycoprotein 644 function by cremophor EL and other surfactants by an in vitro diffusion 645 chamber method using the isolated rat intestinal membranes. *J. Pharm.* 646 *Sci.* **2004**, 93, 877–885.
- (30) Seelig, A.; Gerebtzoff, G. Enhancement of drug absorption by 648 noncharged detergents through membrane and P-glycoprotein binding. 649 Expert Opin. Drug Metab. 2006, 2, 733–752. 650
- (31) Li-Blatter, X.; Seelig, A. Exploring the P-glycoprotein binding 651 cavity with polyoxyethylene alkyl ethers. *Biophys. J.* **2010**, 99, 3589–652 3598.
- (32) Aller, S. G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; 654 Harrell, P. M.; Trinh, Y. T.; Zhang, Q.; Urbatsch, I. L.; Chang, G. 655 Structure of P-glycoprotein reveals a molecular basis for poly-specific 656 drug binding. *Science* **2009**, 323, 1718–1722.
- (33) Li-Blatter, X.; Seelig, A. P-glycoprotein-ATPase modulation: The 658 molecular mechanisms. *Biophys. J.* **2012**, *102*, 1383–1393.
- (34) Edser, C. Latest market analysis. Focus Surfactants 2006, 5, 1–2. 660
- (35) Ying, G.-G. Fate, behavior and effects of surfactants and their 661 degradation products in the environment. *Environ. Pollut.* **2005**, 32, 662 417–431.
- (36) Krogh, K. A.; Halling-Sørensen, B.; Mogensen, B. B.; Vejrup, K. V. 664 Environmental properties and effects of nonionic surfactant adjuvants in 665 pesticides: A review. *Chemosphere* **2003**, *50*, 871–901.